Canaccord Lowers Prestige Consumer Healthcare's Price Target Amid Q4 Weakness

Canaccord Genuity reduced its price target for Prestige Consumer Healthcare (PBH) from $86 to $72 following weaker-than-expected fourth-quarter results, primarily due to soft demand in the eye care segment and external pressures like the Iran conflict. The firm maintains a 'Buy' rating despite the downgrade.

By Laiba Immad Tue, June 2, 2026 at 5:10 PM GMT+3 2 min read · Yahoo Finance · June 2, 2026, 14:10 UTC

Canaccord Lowers Prestige Consumer Healthcare's Price Target Amid Q4 Weakness

Tickers: $PBH

Topics: M&A Activity Pharmaceuticals Stock Price Target Adjustment

Read the full article at Yahoo Finance

More World news

Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC